CA-POSIFLEX
5.1.2022 18:02:06 CET | Business Wire | Press release
Posiflex is pleased to join National Retail Federation’s Big Show for 2022 and will be showcasing its latest point-of-sale solutions in booth #5919. After a two-year-long hiatus from a live NRF show, anticipation is at an all-time high, and Posiflex is excited to exhibit its full line of point-of-sale (POS) terminals, kiosks, tablets and more—along with a few surprises—optimized for retailers in search of powerful and flexible post-pandemic solutions for their operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220105005004/en/
In addition, Posiflex will showcase a new line of POS terminals for today’s retail demands, including the versatile XT7315 , and exciting, fresh models from the new RT6000 Series: the RT6015 and RT6016 .
The XT7315 comes with a wide selection of processors that can suit virtually any point-of-sale requirement. Running on Windows 10 IoT Enterprise OS platform, the XT7315 is housed in a stylish, durable exterior and has a well-designed base that allows for optimal cable management. With its choice of processors, plus a multi-position folding base and a fanless design, the XT7315 continues the excellence of quality and performance that the line of Posiflex XT Series is well-known for.
The new RT6000 Series includes two models: the RT6015 and RT6016, both providing a selection of Intel processors geared for maximum performance and uptime. The main difference between the two models is the display size, with the RT6015 having a 15”/4:3 standard-ratio touch screen display and the RT6016 having a 15.6”/16:9 widescreen-ratio touch screen display. Running on Windows 10 IoT Enterprise and sporting the same exceptional characteristics from the RT Series family, including sleek aesthetics, durability, performance, and reliability, the Posiflex RT6000 Series is an ideal fit for Retail, Hospitality or Specialty-Service establishments.
“With rigorous HALT/HASS testing and total in-house manufacturing that all our products experience, our new XT7315 and RT6000 terminals extend the Posiflex legacy of providing top-notch point-of-sale hardware for today’s challenging atmosphere and customers’ demands,” says Doyle Ledford, VP of Sales & Marketing for Posiflex. “We look forward to introducing these exceptional products along with the rest of our latest solutions at NRF 2022.”
About Posiflex
Since 1984, Posiflex has designed and manufactured award-winning POS terminals and peripherals. Posiflex has since grown exponentially to provide not only full-service POS stations, but also versatile self-service kiosks, state-of-the-art mobile tablets, and scalable embedded PC solutions. Renowned worldwide in the retail and hospitality industries, Posiflex is a proven leader in POS hardware for Windows and Android OS. More than 30 patents and numerous awards have been won for product innovation, design, and reliability. https://www.posiflexusa.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release
CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom